JP2004532900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532900A5 JP2004532900A5 JP2003510677A JP2003510677A JP2004532900A5 JP 2004532900 A5 JP2004532900 A5 JP 2004532900A5 JP 2003510677 A JP2003510677 A JP 2003510677A JP 2003510677 A JP2003510677 A JP 2003510677A JP 2004532900 A5 JP2004532900 A5 JP 2004532900A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- disease
- diaminopurine
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 42
- 108020004707 nucleic acids Proteins 0.000 claims 40
- 102000039446 nucleic acids Human genes 0.000 claims 40
- 239000002773 nucleotide Substances 0.000 claims 29
- 125000003729 nucleotide group Chemical group 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000074 antisense oligonucleotide Substances 0.000 claims 11
- 238000012230 antisense oligonucleotides Methods 0.000 claims 11
- 108091034117 Oligonucleotide Proteins 0.000 claims 10
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 claims 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 8
- 208000023504 respiratory system disease Diseases 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- NIJSNUNKSPLDTO-DJLDLDEBSA-N 2'-deoxytubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 NIJSNUNKSPLDTO-DJLDLDEBSA-N 0.000 claims 4
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims 4
- 206010014950 Eosinophilia Diseases 0.000 claims 4
- DYSDOYRQWBDGQQ-XLPZGREQSA-N N6-Methyl-2'-deoxyadenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 DYSDOYRQWBDGQQ-XLPZGREQSA-N 0.000 claims 4
- DYSDOYRQWBDGQQ-UHFFFAOYSA-N N6-Methyldeoxyadenosine Natural products C1=NC=2C(NC)=NC=NC=2N1C1CC(O)C(CO)O1 DYSDOYRQWBDGQQ-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 239000006199 nebulizer Substances 0.000 claims 4
- 230000007115 recruitment Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 208000025747 Rheumatic disease Diseases 0.000 claims 3
- 208000012931 Urologic disease Diseases 0.000 claims 3
- 229960005305 adenosine Drugs 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 208000010643 digestive system disease Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- -1 phosphotriester Chemical compound 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 210000002345 respiratory system Anatomy 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 208000014001 urinary system disease Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 229940097496 nasal spray Drugs 0.000 claims 2
- 239000007922 nasal spray Substances 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010049153 Allergic sinusitis Diseases 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 206010028741 Nasal inflammation Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 claims 1
- 239000013081 microcrystal Substances 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000101 thioether group Chemical group 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30307101P | 2001-07-06 | 2001-07-06 | |
| US60/303,071 | 2001-07-06 | ||
| PCT/CA2002/001046 WO2003004511A2 (en) | 2001-07-06 | 2002-07-08 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004532900A JP2004532900A (ja) | 2004-10-28 |
| JP2004532900A5 true JP2004532900A5 (enExample) | 2006-01-05 |
| JP4903984B2 JP4903984B2 (ja) | 2012-03-28 |
Family
ID=23170407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003510677A Expired - Fee Related JP4903984B2 (ja) | 2001-07-06 | 2002-07-08 | オリゴヌクレオチドのｉｎｖｉｖｏでの効率を増加するおよび哺乳動物において炎症を阻害するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7745420B2 (enExample) |
| EP (1) | EP1406667B1 (enExample) |
| JP (1) | JP4903984B2 (enExample) |
| AT (1) | ATE386548T1 (enExample) |
| AU (1) | AU2002319033B2 (enExample) |
| CA (1) | CA2451738C (enExample) |
| DE (1) | DE60225141T2 (enExample) |
| DK (1) | DK1406667T3 (enExample) |
| ES (1) | ES2301659T3 (enExample) |
| MX (1) | MXPA04000162A (enExample) |
| NZ (1) | NZ530360A (enExample) |
| PT (1) | PT1406667E (enExample) |
| WO (1) | WO2003004511A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045202A1 (en) * | 2004-10-29 | 2006-05-04 | Topigen Pharmaceuticals Inc. | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
| ES2373246T3 (es) | 2006-08-11 | 2012-02-01 | Prosensa Technologies B.V. | Oligonucleótidos monocatenarios complementarios de elementos repetitivos para el tratamiento de trastornos genéticos asociados a la inestabilidad de repeticiones de adn. |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| HUE028662T2 (en) | 2007-10-26 | 2016-12-28 | Academisch Ziekenhuis Leiden | Preparations and methods for controlling muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| EP2285961A4 (en) * | 2008-05-15 | 2012-10-17 | Topigen Pharmaceuticals Inc | OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION |
| WO2010048731A1 (en) * | 2008-10-31 | 2010-05-06 | Christopher John Ong | Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents |
| US9622909B2 (en) | 2009-02-26 | 2017-04-18 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
| MY183870A (en) * | 2009-02-26 | 2021-03-17 | Advanced Cooling Therapy Llc | Devices and methods for controlling patient temperature |
| US9301871B2 (en) | 2009-02-26 | 2016-04-05 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
| US9326890B2 (en) | 2009-02-26 | 2016-05-03 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
| SG192869A1 (en) * | 2011-02-24 | 2013-09-30 | Pharmaxis Ltd | Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine |
| CN111893117B (zh) | 2012-01-27 | 2024-06-04 | 比奥马林技术公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| US9272016B2 (en) * | 2012-04-20 | 2016-03-01 | University Of Iowa Research Foundation | Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells |
| HRP20171254T1 (hr) * | 2012-04-23 | 2018-01-12 | Biomarin Technologies B.V. | Oligonukleotidi koji moduliraju rnk s poboljšanim karakteristikama za liječenje neuromišićnih poremećaja |
| FR3057774B1 (fr) * | 2016-10-21 | 2025-11-07 | Museum Nat Dhistoire Naturelle | Derives de la purine pour leur utilisation dans le traitement ou la prevention de maladies dues a une mutation non-sens |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3337530A (en) | 1965-09-20 | 1967-08-22 | Upjohn Co | Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety |
| JPH01173818A (ja) * | 1987-12-28 | 1989-07-10 | Aisin Aw Co Ltd | 車両用ナビゲーション装置 |
| US5523205A (en) * | 1988-08-02 | 1996-06-04 | Institut Pasteur | DNA probes specific for hemolytic listeria |
| US5646265A (en) * | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5112961A (en) * | 1990-07-18 | 1992-05-12 | Schering Corporation | Dna encoding subunits of a high affinity gm-csf receptor |
| EP0509826A1 (en) * | 1991-04-19 | 1992-10-21 | Schering Corporation | Subunit of the human interleukin 3 receptor |
| US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
| GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US6077668A (en) * | 1993-04-15 | 2000-06-20 | University Of Rochester | Highly sensitive multimeric nucleic acid probes |
| CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| EP1088066B1 (en) * | 1998-06-19 | 2006-11-29 | McGILL UNIVERSITY | Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues |
| CA2333901A1 (en) * | 1998-08-03 | 2000-02-24 | East Carolina University | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
| US6175004B1 (en) * | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
| IL140054A0 (en) | 1999-04-06 | 2002-02-10 | Univ East Carolina | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion |
-
2002
- 2002-07-08 DK DK02748499T patent/DK1406667T3/da active
- 2002-07-08 PT PT02748499T patent/PT1406667E/pt unknown
- 2002-07-08 EP EP02748499A patent/EP1406667B1/en not_active Expired - Lifetime
- 2002-07-08 JP JP2003510677A patent/JP4903984B2/ja not_active Expired - Fee Related
- 2002-07-08 NZ NZ530360A patent/NZ530360A/en not_active IP Right Cessation
- 2002-07-08 US US10/482,949 patent/US7745420B2/en not_active Expired - Fee Related
- 2002-07-08 AT AT02748499T patent/ATE386548T1/de active
- 2002-07-08 AU AU2002319033A patent/AU2002319033B2/en not_active Ceased
- 2002-07-08 ES ES02748499T patent/ES2301659T3/es not_active Expired - Lifetime
- 2002-07-08 CA CA2451738A patent/CA2451738C/en not_active Expired - Fee Related
- 2002-07-08 WO PCT/CA2002/001046 patent/WO2003004511A2/en not_active Ceased
- 2002-07-08 DE DE60225141T patent/DE60225141T2/de not_active Expired - Lifetime
- 2002-07-08 MX MXPA04000162A patent/MXPA04000162A/es active IP Right Grant
-
2009
- 2009-05-06 US US12/436,493 patent/US20100286235A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532900A5 (enExample) | ||
| US20100286235A1 (en) | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | |
| ES2295148T3 (es) | Analogos nucleosidos con base monociclica de carboximidina modificada. | |
| CN105873902B (zh) | 用于rna递送的可电离的阳离子脂质 | |
| CN109689672B (zh) | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 | |
| HUP0302334A2 (hu) | Vírusellenes hatású nukleozid-vegyületek prekurzorjai, valamint e vegyületek alkalmazása gyógyászati készítmények előállítására | |
| JP2024071397A5 (enExample) | ||
| US6025339A (en) | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation | |
| US7427606B2 (en) | Method to reduce inflammatory response in transplanted tissue | |
| JP2001513568A (ja) | 肺疾患を治療するためのウリジン５’−ジホスフェートとその類似体の使用 | |
| WO1998023294A9 (en) | Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation | |
| US20180222863A1 (en) | Ionizable cationic lipid for rna delivery | |
| AU2002319033A1 (en) | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | |
| TW202340466A (zh) | 一種ｄｓｒｎａ、其製備方法及應用 | |
| TW201919654A (zh) | 用於抑制α-ENaC表現之RNAi試劑及使用方法 | |
| TW202130809A (zh) | 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法 | |
| CA2477241A1 (en) | Compositions and methods for treating epithelial and retinal tissue diseases | |
| TW202412845A (zh) | 用於遞送治療劑至cns組織之脂質結合物 | |
| CN118525092A (zh) | 一种dsRNA、其应用及制备方法 | |
| KR20000070167A (ko) | 질병의 시토킨 관련 치료 방법 | |
| JP2021500903A5 (enExample) | ||
| WO2023138650A1 (zh) | 一种dsRNA、其应用及制备方法 | |
| WO2022250072A1 (ja) | 心疾患治療薬 | |
| WO2025000059A1 (en) | Compounds and uses therefor | |
| US20090004101A1 (en) | Method and Means for Enhanced Pulmonary Drug Delivery |